Masitinib in Neurology
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative, life-threatening disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons. While the average survival time is 3 years, about 10 percent of people with ALS will survive 10 years. Preclinical studies show that masitinib is capable of exerting neuroprotection in both the central and peripheral nervous…